HB
ALXN

Harry Burn’s Alexion Pharmaceuticals ALXN Stock Holding History

Harry Burn’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,348,591
Closed -$132M – 39
2019
Q3 		$132M Sell
1,348,591
-35,633
-3% -$4.02M 2.74% 19
2019
Q2 		$181M Buy
1,384,224
+200,600
+17% +$25.9M 3.52% 6
2019
Q1 		$160M Buy
1,183,624
+142,318
+14% +$17.7M 3.08% 11
2018
Q4 		$101M Sell
1,041,306
-153,257
-13% -$18.1M 2.09% 33
2018
Q3 		$166M Buy
1,194,563
+110,469
+10% +$13.9M 2.84% 18
2018
Q2 		$135M Buy
+1,084,094
New +$127M 2.26% 28

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Harry Burn's ALXN Position: Q4 2019 in Review

Harry Burn sold out of Alexion Pharmaceuticals (ALXN) in Q4 2019, closing a stake of 1,348,591 shares — an estimated $132M sold.

Harry Burn first reported a position in ALXN in Q2 2018 and held it in 6 quarters. The position peaked at $181M in Q2 2019. 668 funds tracked by Wall St. Rank hold ALXN as of Q4 2019.

  • Harry Burn reported no remaining Alexion Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Harry Burn sold 1,348,591 Alexion Pharmaceuticals shares in Q4 2019, an estimated $132M.
  • Harry Burn first reported a position in Alexion Pharmaceuticals in Q2 2018 and held it in 6 quarters.
  • Harry Burn's Alexion Pharmaceuticals position peaked at $181M in Q2 2019.
  • 668 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2019.

Based on Sound Shore Management's 13F filing for Q4 2019, filed 6 Feb 2020.